News & Articles

First patients are expected to be enrolled shortly and additional European regulatory approvals are in process

The platform aims to help researchers generate a clearer view of the current state of research and gain invaluable insights

People who recovered from COVID-19 shows that most individuals had generated antibodies that were intrinsically capable of neutralizing the SARS-CoV-2 virus

Microsemi CRP hematology analyzers have been installed during COVID-19 ‘lockdown’ in POC locations to help reduce hospital admissions

Discover how clinicians at the Center for Personalized Medicine identify and track different coronavirus strains

Register for this webinar to discover how pancreatic cancer-derived organoids can be used as a predictive tool for personalized medicine

Cambridge Cognition has secured over $1.5 million in new contracts to support pharmaceutical clients in delivering virtual clinical trials

The cPass™ – SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit aims to detect the presence of neutralizing antibodies in an hour

As a cryogenic supplier, Air Products looks at both modes of sample storage and compares them in terms of accessibility, reliability and temperature

The company aims to ramp up its production capacity of more than 50 million antibody tests per month

Test will be available at NHS laboratories across the UK, using its ARCHITECT i1000SR and i2000SR and Alinity i laboratory instruments

Interim clinical study data shows ID NOW test performance of 94.7% sensitivity and 98.6% specificity

Driven by the gap in COVID-19 testing, the collaboration aims to create a fully disposable, rapid and handheld test for consumers

COVID-DPR is a virtual collection of high-resolution microscopic COVID-related human tissue images hosted at the National Institutes of Health

A qualitative test for the detection of nucleic acid from SARS-CoV-2

Study suggests that type I IFN deficiency in the blood could help define a high-risk population

The COVID-19 vaccine trial is part of a global development program that will uncover the safety and immunogenicity of four mRNA vaccine candidates.

Test deployed on Quanterix' Simoa platform promises 1,000-fold sensitivity improvement

Science industry comes together online to share knowledge and provide technology solutions for cancer and immunology research